NASDAQ:NVCR NovoCure (NVCR) Stock Forecast, Price & News $71.81 +0.77 (+1.08%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$71.08▼$73.4150-Day Range$56.44▼$80.8452-Week Range$56.06▼$120.03Volume2.46 million shsAverage Volume890,999 shsMarket Capitalization$7.63 billionP/E RatioN/ADividend YieldN/APrice Target$84.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability NovoCure MarketRank™ ForecastAnalyst RatingHold2.17 Rating ScoreUpside/Downside16.4% Upside$84.33 Price TargetShort InterestBearish7.70% of Shares Sold ShortDividend StrengthN/ASustainability-1.15Upright™ Environmental ScoreNews Sentiment1.42Based on 3 Articles This WeekInsider TradingSelling Shares$621,533 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.97) to ($2.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.68 out of 5 starsMedical Sector844th out of 1,006 stocksSurgical & Medical Instruments Industry86th out of 104 stocks 2.1 Analyst's Opinion Consensus RatingNovoCure has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 3 buy ratings, 1 hold rating, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $84.33, NovoCure has a forecasted upside of 16.4% from its current price of $72.45.Amount of Analyst CoverageNovoCure has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted7.70% of the outstanding shares of NovoCure have been sold short.Short Interest Ratio / Days to CoverNovoCure has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.Change versus previous monthShort interest in NovoCure has recently increased by 5.82%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNovoCure does not currently pay a dividend.Dividend GrowthNovoCure does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNovoCure has received a 68.17% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Brain cancer medication", and "Cabozantinib" products. See details.Environmental SustainabilityThe Environmental Impact score for NovoCure is -1.15. Previous Next 3.6 News and Social Media Coverage News SentimentNovoCure has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for NovoCure this week, compared to 3 articles on an average week.Search Interest19 people have searched for NVCR on MarketBeat in the last 30 days. This is an increase of 375% compared to the previous 30 days.MarketBeat Follows8 people have added NovoCure to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NovoCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $621,533.00 in company stock.Percentage Held by InsidersOnly 6.22% of the stock of NovoCure is held by insiders.Percentage Held by Institutions78.42% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for NovoCure are expected to decrease in the coming year, from ($1.97) to ($2.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovoCure is -54.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovoCure is -54.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovoCure has a P/B Ratio of 17.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NovoCure (NASDAQ:NVCR) StockNovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.Read More Receive NVCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. Email Address NVCR Stock News HeadlinesMay 19, 2023 | americanbankingnews.comNovoCure (NASDAQ:NVCR) Lifted to Overweight at Wells Fargo & CompanyMay 19, 2023 | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) Receives $84.83 Consensus Target Price from BrokeragesMay 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 18, 2023 | americanbankingnews.comNovoCure (NASDAQ:NVCR) Research Coverage Started at StockNews.comMay 16, 2023 | msn.comWells Fargo Upgrades NovoCure (NVCR)May 16, 2023 | msn.comUnusual Call Option Trade in NovoCure (NVCR) Worth $500.00KMay 16, 2023 | msn.comNovoCure gains as Wells Fargo upgrades on upcoming data readoutMay 16, 2023 | cnbc.comThis biotech stock could yield 33% upside ahead of cancer trial data, Wells Fargo saysMay 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 16, 2023 | markets.businessinsider.com4 Analysts Have This to Say About NovoCureMay 11, 2023 | americanbankingnews.comNovoCure (NASDAQ:NVCR) Upgraded at StockNews.comMay 7, 2023 | americanbankingnews.comNovoCure (NASDAQ:NVCR) PT Lowered to $115.00 at HC WainwrightMay 5, 2023 | finance.yahoo.comNovoCure Limited's (NASDAQ:NVCR) Business Is Trailing The Industry But Its Shares Aren'tMay 4, 2023 | finance.yahoo.comNovoCure (NVCR) Reports Q1 Loss, Lags Revenue EstimatesMay 4, 2023 | finance.yahoo.comNovoCure (NVCR) Q1 2023 Earnings Call TranscriptMay 4, 2023 | seekingalpha.comNovoCure Limited 2023 Q1 - Results - Earnings Call PresentationMay 2, 2023 | americanbankingnews.comNovoCure (NVCR) to Release Earnings on ThursdayApril 26, 2023 | finance.yahoo.comNovocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingApril 24, 2023 | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) Receives $87.33 Consensus Target Price from AnalystsApril 14, 2023 | finance.yahoo.comNovocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023April 6, 2023 | finance.yahoo.comNovoCure (NASDAQ:NVCR) shareholder returns have been solid, earning 194% in 5 yearsApril 1, 2023 | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) Receives Consensus Recommendation of "Hold" from AnalystsMarch 29, 2023 | finance.yahoo.comKristin Stafford Joins Novocure Board of DirectorsMarch 27, 2023 | seekingalpha.comNovoCure: Pipeline Conversion Is KeyMarch 20, 2023 | seekingalpha.comExploring The Potential Of NovoCure's TTFields In Non-Small Cell Lung CancerMarch 16, 2023 | finance.yahoo.comInstitutional investors may adopt severe steps after NovoCure Limited's (NASDAQ:NVCR) latest 7.3% drop adds to a year lossesMarch 1, 2023 | finance.yahoo.comNovocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in FranceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NVCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. Email Address NVCR Company Calendar Last Earnings5/04/2023Today5/31/2023Next Earnings (Estimated)7/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVCR CUSIPN/A CIK1645113 Webwww.novocure.com Phone441534756700FaxN/AEmployees1,320Year FoundedN/APrice Target and Rating Average Stock Price Forecast$84.33 High Stock Price Forecast$115.00 Low Stock Price Forecast$50.00 Forecasted Upside/Downside+15.7%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,530,000.00 Net Margins-26.98% Pretax Margin-24.96% Return on Equity-32.03% Return on Assets-11.99% Debt Debt-to-Equity Ratio1.31 Current Ratio7.32 Quick Ratio7.11 Sales & Book Value Annual Sales$537.84 million Price / Sales14.39 Cash FlowN/A Price / Cash FlowN/A Book Value$4.07 per share Price / Book17.91Miscellaneous Outstanding Shares106,210,000Free Float99,603,000Market Cap$7.74 billion OptionableOptionable Beta0.81 Key ExecutivesAsaf DanzigerChief Executive Officer & DirectorWilhelmus C. M. GroenhuysenChief Operating OfficerAshley CordovaChief Financial OfficerMoshe GiladiChief Science OfficerPiet HinoulSenior Vice President & Head-MedicalKey CompetitorsStevanato GroupNYSE:STVNInspire Medical SystemsNYSE:INSPGlobus MedicalNYSE:GMEDShockwave MedicalNASDAQ:SWAVMerit Medical SystemsNASDAQ:MMSIView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 2,738 shares on 5/26/2023Ownership: 0.007%Ameriprise Financial Inc.Sold 1,218 shares on 5/22/2023Ownership: 0.009%New York State Common Retirement FundSold 87,571 shares on 5/18/2023Ownership: 0.119%Frontier Capital Management Co. LLCSold 21,239 shares on 5/16/2023Ownership: 0.302%Belpointe Asset Management LLCSold 218 shares on 5/16/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions NVCR Stock - Frequently Asked Questions Should I buy or sell NovoCure stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVCR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCR, but not buy additional shares or sell existing shares. View NVCR analyst ratings or view top-rated stocks. What is NovoCure's stock price forecast for 2023? 6 equities research analysts have issued 12 month price objectives for NovoCure's stock. Their NVCR share price forecasts range from $50.00 to $115.00. On average, they predict the company's share price to reach $84.33 in the next year. This suggests a possible upside of 15.7% from the stock's current price. View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts. How have NVCR shares performed in 2023? NovoCure's stock was trading at $73.35 at the start of the year. Since then, NVCR shares have decreased by 0.6% and is now trading at $72.89. View the best growth stocks for 2023 here. When is NovoCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023. View our NVCR earnings forecast. How were NovoCure's earnings last quarter? NovoCure Limited (NASDAQ:NVCR) posted its quarterly earnings results on Thursday, May, 4th. The medical equipment provider reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.14. The medical equipment provider earned $122.20 million during the quarter, compared to analyst estimates of $127.93 million. NovoCure had a negative net margin of 26.98% and a negative trailing twelve-month return on equity of 32.03%. NovoCure's revenue for the quarter was down 11.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.04) EPS. What ETFs hold NovoCure's stock? ETFs with the largest weight of NovoCure (NASDAQ:NVCR) stock in their portfolio include BlueStar Israel Technology ETF (ITEQ), VanEck Israel ETF (ISRA), Principal Healthcare Innovators ETF (BTEC), First Trust Indxx Medical Devices ETF (MDEV), Strategas Global Policy Opportunities ETF (SAGP), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and BlackRock Future Health ETF (BMED). What is Asaf Danziger's approval rating as NovoCure's CEO? 17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees. What other stocks do shareholders of NovoCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy Partners (VNOM), Roku (ROKU), Salesforce (CRM) and Block (SQ). What is NovoCure's stock symbol? NovoCure trades on the NASDAQ under the ticker symbol "NVCR." Who are NovoCure's major shareholders? NovoCure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (14.88%), Baillie Gifford & Co. (8.10%), BlackRock Inc. (7.84%), Price T Rowe Associates Inc. MD (2.50%), Geode Capital Management LLC (1.32%) and Credit Suisse AG (0.83%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle. View institutional ownership trends. How do I buy shares of NovoCure? Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NovoCure's stock price today? One share of NVCR stock can currently be purchased for approximately $72.89. How much money does NovoCure make? NovoCure (NASDAQ:NVCR) has a market capitalization of $7.74 billion and generates $537.84 million in revenue each year. The medical equipment provider earns $-92,530,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. How many employees does NovoCure have? The company employs 1,320 workers across the globe. How can I contact NovoCure? NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The official website for the company is www.novocure.com. The medical equipment provider can be reached via phone at 441534756700 or via email at investorinfo@novocure.com. This page (NASDAQ:NVCR) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.